Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review
- PMID: 23041539
- PMCID: PMC3501546
- DOI: 10.1016/j.cgh.2012.10.001
Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review
Abstract
Background & aims: Nonalcoholic fatty liver disease (NAFLD) has been implicated as a cause of hepatocellular carcinoma (HCC). We performed a systematic review of epidemiology studies to confirm the association between these disorders.
Methods: We searched PubMed for original reports published from January 1992 to December 2011 that evaluated the association between NAFLD, nonalcoholic steatohepatitis (NASH), cryptogenic cirrhosis presumed to be NASH-related, and the risk of HCC. Studies were categorized as offering potential direct evidence (eg, cohort studies) or indirect evidence (eg, case-control, cross-sectional, or case-series studies) for an association. We analyzed data from a total of 17 cohort studies (3 population based, 9 clinic based [6 limited to patients with cirrhosis], and 5 natural history), 18 case-control and cross-sectional studies, and 26 case series.
Results: NAFLD or NASH cohorts with few or no cases of cirrhosis cases had a minimal risk for HCC (cumulative HCC mortality of 0%-3% for study periods up to 20 y). Cohorts with NASH and cirrhosis had a consistently higher risk (cumulative incidence ranging from 2.4% over 7 y to 12.8% over 3 y). However, the risk for HCC was substantially lower in these cohorts than for cohorts with hepatitis C-related cirrhosis. Factors that increased risk among cohorts with NASH and cirrhosis could not be determined, because most studies were not sufficiently powered for multivariate analysis.
Conclusions: This systematic review shows that despite several limitations, there is epidemiologic evidence to support an association between NAFLD or NASH and an increased risk of HCC; risk seems to be limited to individuals with cirrhosis.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.Hepatology. 2010 Jun;51(6):1972-8. doi: 10.1002/hep.23527. Hepatology. 2010. PMID: 20209604
-
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7. Dig Dis Sci. 2015. PMID: 26250831
-
Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis.Trop Gastroenterol. 2013 Jul-Sep;34(3):159-63. doi: 10.7869/tg.120. Trop Gastroenterol. 2013. PMID: 24851525
-
Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.Neoplasia. 2022 Aug;30:100809. doi: 10.1016/j.neo.2022.100809. Epub 2022 May 27. Neoplasia. 2022. PMID: 35636146 Free PMC article. Review.
-
Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.Hepatology. 2010 May;51(5):1820-32. doi: 10.1002/hep.23594. Hepatology. 2010. PMID: 20432259 Review.
Cited by
-
Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?Int J Biol Sci. 2020 Jun 23;16(13):2367-2378. doi: 10.7150/ijbs.47143. eCollection 2020. Int J Biol Sci. 2020. PMID: 32760204 Free PMC article. Review.
-
Identifying High-Risk NASH Patients: What We Know so Far.Hepat Med. 2020 Aug 21;12:125-138. doi: 10.2147/HMER.S265473. eCollection 2020. Hepat Med. 2020. PMID: 32982495 Free PMC article. Review.
-
Surveillance for hepatocellular carcinoma.J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S50-6. doi: 10.1016/j.jceh.2014.03.050. Epub 2014 Apr 21. J Clin Exp Hepatol. 2014. PMID: 25755611 Free PMC article. Review.
-
Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.Int J Mol Sci. 2021 May 9;22(9):5016. doi: 10.3390/ijms22095016. Int J Mol Sci. 2021. PMID: 34065108 Free PMC article. Review.
-
Prognostic Score-based Clinical Factors and Metabolism-related Biomarkers for Predicting the Progression of Hepatocellular Carcinoma.Evol Bioinform Online. 2020 Sep 22;16:1176934320951571. doi: 10.1177/1176934320951571. eCollection 2020. Evol Bioinform Online. 2020. PMID: 33013158 Free PMC article.
References
-
- El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–823. - PubMed
-
- El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37(Suppl 2):S88–S94. - PubMed
-
- Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863–869. - PubMed
-
- Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical